Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.54 |
| ▸ | CFTR | P13569 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396446 | 0.84 | NOTUM (0.41) | SOS1NOTUMCFTRCES2 | |
| SCHEMBL23065961 | 0.84 | NOTUM (0.54) | SOS1NOTUMCFTRKDM4EGPR35 | |
| SCHEMBL30033650 | 0.83 | CFTR (0.55) | SOS1NOTUMCFTRKDM4EGPR35 | |
| SCHEMBL28749071 | 0.83 | SOS1 (0.61) | SOS1NOTUMCFTRMRGPRX4KDM4E | |
| SCHEMBL25355994 | 0.82 | CFTR (0.50) | SOS1NOTUMCFTRMRGPRX4KDM4E | |
| SCHEMBL25405482 | 0.81 | NOTUM (0.39) | SOS1NOTUMKDM4ECES2MAPT | |
| SCHEMBL9222372 | 0.81 | CFTR (0.49) | SOS1NOTUMCFTRMRGPRX4KDM4E | |
| SCHEMBL31187835 | 0.81 | NOTUM (0.54) | SOS1NOTUMCFTRMRGPRX4KDM4E | |
| SCHEMBL2657595 | 0.81 | MRGPRX4 (0.51) | SOS1NOTUMCFTRMRGPRX4KDM4E | |
| SCHEMBL23065962 | 0.80 | NOTUM (0.50) | SOS1NOTUMCFTRMRGPRX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | BACE2, PSEN2, BACE1 | SOS1 4499/4885NOTUM 571/4885CFTR 2316/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | SOS1 4152/4885NOTUM 1414/4885CFTR 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.